07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Ethypharm, Lansen Pharmaceutical sales and marketing update

Ethypharm granted Lansen's Ningbo Lansen Pharmaceutical Co. Ltd. subsidiary exclusive rights to commercialize ketoprofen/omeprazole in China. Ethypharm will be responsible for developing the compound and obtaining an Import Drug License from the China's State Food...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Ethypharm, Meda sales and marketing update

The companies added Eastern European, Russian and Turkish rights to a 2007 deal granting Meda exclusive rights to market Ethypharm's Axorid ketoprofen/ omeprazole combination product in Central and Western Europe. The combination of an NSAID...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

4Q approvals

4Q approvals...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

Ketoprofen/omeprazole regulatory update

Meda AB (SSE:MEDA, Solna, Sweden) said the U.K. approved the company's ketoprofen/omeprazole combination product to treat pain and inflammation. The combination of an NSAID and a proton pump inhibitor (PPI) is under review in several...
01:21 , Dec 10, 2008 |  BC Extra  |  Company News

U.K. approves ketoprofen/omeprazole combination

Meda (SSE:MEDA) said the U.K. approved the company's ketoprofen/ omeprazole combination product to treat pain and inflammation. The combination of an NSAID and a proton pump inhibitor (PPI) is under review in several other European...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Ethypharm, Meda deal

MEDA received exclusive rights to market a ketoprofen/omeprazole combination product in certain European territories to treat pain and inflammation. Ethypharm received E3 million ($4.1 million) up front and is eligible for E6 million in milestones....